Radyoterapi Sonrası Yan Etki İçin Puanlama Sistemleri
Özet
Bu çalışma, kanser tedavisinde kritik bir rol oynayan radyoterapi sonrasında normal dokularda gelişen akut (ilk 3 ay) ve kronik (6 ay sonrası) advers olayların/toksisitenin değerlendirilmesi amacıyla geliştirilen uluslararası puanlama sistemlerini incelemektedir. Tedavinin temel hedefi tümör kontrolünü maksimuma çıkarırken normal dokuları korumak olup, oluşan yan etkileri raporlamada ortak bir klinik dil oluşturmak büyük önem taşır. Bu amaçla geliştirilen WHO, EORTC/RTOG, CTCAE ve doku hasarını subjektif, objektif, yönetimsel ve analitik olarak dört kategoride detaylandıran LENT/SOMA derecelendirme sistemleri, yan etkilerin şiddetini hafiften ölüme kadar (Grade 1-5) sınıflandırarak radyasyon onkologlarının günlük pratiklerinde toksisiteyi doğru yönetmelerini ve merkezler arası veri standardizasyonunu sağlar.
This study reviews international scoring systems developed to evaluate acute (first 3 months) and chronic (after 6 months) adverse events/toxicity in normal tissues following radiotherapy, a critical modality in cancer treatment. The primary goal of therapy is maximizing tumor control while sparing normal tissues, making a standardized clinical language essential for reporting side effects. For this purpose, grading systems like WHO, EORTC/RTOG, CTCAE, and LENT/SOMA—which details tissue damage across subjective, objective, management, and analytic categories—classify toxicity severity from mild to fatal (Grades 1-5), enabling radiation oncologists to effectively manage side effects and ensure data standardization across centers.
Referanslar
Abdel-Wahab M, Gondhowiardjo SS, Accioly AR, et al. Global Radiotherapy: Current Status and Future Directions—White Paper. JCO Glob Oncol. 2021;7:827-842.
Paulo Nuno Martins. A brief history about radiotherapy. IJLRET. 2018;4(2):8-11.
Smita Kayal. Cancer Therapy: A Brief Outline. Ann Natl Acad Med Sci (India) 2019;55:138–144.
Sun J, Wei Q, Zhou Y, Wang J, Liu Q, Xu H. A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol. 2017;11(Suppl 5):87.
Baskar R, Lee KA, Yeo R, Yeohet KW. Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences. 2012;9(3):193
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys. 1991;21:109.
WHO Handbook for reporting results of Cancer Treatment. WHO offset publication No. 48 Neoplasma 1980; 20: 37-46.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-1346.
Pavy JJ, Denekamp J, Letschert J, Littbrand B, et al. Late effects toxicity scoring: the SOMA scale. Radiother Oncol. 35: 11–1511. Ródenas C, Gómez J, Soto J, et al. Natural radioactivity of spring water used as spas in Spain. Journal of Radioanalytical and Nuclear Chemistry. 2008;277(3):625-630.
Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.
